Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase -2-selective inhibition

American Journal of Medicine

Volumn 107, Issue 6 SUPPL. 1, 1999, Pages 65-70

  Brater, D Craig ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CELECOXIB; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBUPROFEN; INDOMETACIN; MELOXICAM; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SULINDAC; THIAZIDE DIURETIC AGENT;

ANALGESIC NEPHROPATHY; ARTHRITIS; CONFERENCE PAPER; EDEMA; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERKALEMIA; INTERSTITIAL NEPHRITIS; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FUNCTION; POTASSIUM EXCRETION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RISK FACTOR; SODIUM EXCRETION; WEIGHT GAIN;

EID: 0033428385     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(99)00369-1     Document Type: Conference Paper

References (41)

1. Clive DM, Stoff JS. Renal syndromes associated with non-steroidal antiinflammatory drugs. N Engl J Med. 1984;310: 563-572.
2. Garella S, Matarese RA. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine. 1984;63:165-181.
3. Carmichael J, Shankel SW. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med. 1985;78:992-1000.
4. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int. 1987;32:1-12.
5. 2 across the isolated, perfused rabbit collecting tubule. J Clin Invest. 1977;59:1099-1104.
6. Kaojarern S, Chennavasin P, Anderson S, Brater DC. Nephron site of effect of nonsteroidal anti-inflammatory drugs on solute excretion in humans. Am J Physiol. 1983; 244:134-139.
7. Chennavasin P, Seiwell R, Brater DC. Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. J Pharmacol Exp Ther. 1980;215:77-81.
8. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? Ann Intern Med. 1994;121:289-300.
9. de Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension. Drugs. 1996;51:179-187.
10. Murray MD, Lazaridis EN, Brizendine E, Haag K, Becker P, Brater DC. The effect of nonsteroidal anti-inflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency. Am J Med Sci. 1997;314:80-88.
11. Tan SY, Shapiro R, Franco R, Stockard H, Mulrow PJ. Indomethacin-induced prostaglandin inhibition with hyperkalemia. Ann Intern Med. 1979;90:783-785.
12. Frölich JC, Hollifield JW, Dormois JC, et al. Suppression of plasma renin activity by indomethacin in man. Circ Res. 1976;39:447-452.
13. Romero JC, Dunlap CL, Strong CG. The effect of indomethacin and other anti-inflammatory drugs on the renin-angiotensin system. J Clin Invest. 1976;58:282-288.
14. Zimran A, Kramer M, Plaskin M, Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. BMJ. 1985;291:107-108.
15. Brater DC, Anderson SA, Baird B, Campbell WB. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in man. Kidney Int. 1985;27:66-73.
16. Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DC. Effects of acute and chronic dosing of nonsteroidal anti-inflammatory drugs in patients with renal insufficiency. Kidney Int. 1986;30:760-768.
17. 2 during sodium depletion in the dog. J Clin Invest. 1980;66:748-756.
18. Muther RS, Potter DM, Bennett WM. Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance. Ann Intern Med. 1981;94:317-321.
19. Murray MD, Black PK, Kuzmik DD, Haag KM, Manaatunga AK, Mullin MA, Hall SD, Brater DC. Acute and chronic effects of nonsteroidal anti-inflammatory drugs on glomerular filtration rate in elderly patients. Am J Med Sci. 1995; 310:188-197.
20. Henry D, Page J, Whyte I, Nanra R, Hall C. Consumption of nonsteroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects: results of a case-control study. Br J Clin Pharmacol. 1997;44:85-90.
21. Porile JL, Bakris GL, Garella S. Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. J Clin Pharmacol. 1990;30:468-475.
22. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis. 1996;27:162-165.
23. Sandler DP, Burr FB, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med. 1991;115:165-172.
24. DeBroe M, Elseviers MM. Analgesic nephropathy. N Engl J Med. 1998;338:446-452.
25. Ciabattoni G, Cinotti GA, Pieruggi A, et al. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. N Engl J Med. 1984;310:279-283.
26. Roberts DG, Gerber JG, Barnes JS, Zerbe GO, Nies AS. Sulindac is not renal sparing in man. Clin Pharmacol Ther. 1985;38:258-265.
27. Berg KJ, Talseth T. Acute renal effects of sulindac and indomethacin in chronic renal failure. Clin Pharmacol Ther. 1985;37:447-452.
28. Giannessi D, Lazzerini G, Filipponi P, et al. Effects of nabumetone, a new nonsteroidal anti-inflammatory drug, on urinary prostaglandin excretion in man. Pharmacol Res. 1993; 28:229-241.
29. Cipollone F, Ganci A, Panara MR, et al. Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther. 1995;58:335-341.
30. Freed MI, Audet PR, Zariffa N, et al. Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers. J Clin Pharmacol. 1994;34:1098-1108.
31. Cook ME, Wallin JD, Thakur VD, et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol. 1997;24:1137-1144.
32. Simon LS. Nonsteroidal antiinflammatory drugs and their effects: the importance of COX "selectivity." J Clin Rheumatol. 1996;2:135-140.
33. Jouzeau JY, Terlain B, Abid A, Nédélec E, Netter P. Cyclooxygenase isoenzymes. Drugs. 1997;53:563-582.
34. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378:406-409.
35. Schneider A, Stahl RAK. Cyclooxygenase-2 (COX-2) and the kidney: current status and potential perspectives. Nephrol Dial Transplant. 1998;13:10-12.
36. Harris RC, McKanna JA, Alcai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94:2504-2510.
37. Tomasoni S, Noris M, Zappella S, et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol. 1993;9:1202-1212.
38. Müller FO, Middle MV, Schall R, Terblanché J, Hundt HKL, Groenewoud G. An evaluation of the interaction of meloxicam with furosemide in patients with compensated chronic cardiac failure. Br J Clin Pharmacol. 1997;44:393-398.
39. Stichtenoth DO, Wagner B, Frölich JC. Effect of selective inhibition of the inducible cyclooxygenase on renin release in health volunteers. J Invest Med. 1998;46:290-296.
40. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-741.
41. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96:272-277.